Sign in or Register   Sign in or Register
  |  

Mouse Anti-PEX5 Recombinant Antibody (1D3) (CBMAB-P1482-YC)

Provided herein is a Mouse monoclonal antibody against Human Peroxisomal Biogenesis Factor 5. The antibody can be used for immunoassay techniques, such as IF, WB.
See all PEX5 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
1D3
Antibody Isotype
IgG1
Application
IF, WB

Basic Information

Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
PBS, pH 7.3, 1% BSA, 50% glycerol, 0.02% sodium azide
Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Peroxisomal Biogenesis Factor 5
Introduction
PEX5 binds to the C-terminal PTS1-type tripeptide peroxisomal targeting signal (SKL-type) and plays an essential role in peroxisomal protein import. Peroxins (PEXs) are proteins that are essential for the assembly of functional peroxisomes. The peroxisome biogenesis disorders (PBDs) are a group of genetically heterogeneous autosomal recessive, lethal diseases characterized by multiple defects in peroxisome function. The peroxisomal biogenesis disorders are a heterogeneous group with at least 14 complementation groups and with more than 1 phenotype being observed in cases falling into particular complementation groups. Although the clinical features of PBD patients vary, cells from all PBD patients exhibit a defect in the import of one or more classes of peroxisomal matrix proteins into the organelle.
Entrez Gene ID
5830
UniProt ID
P50542
Alternative Names
Peroxisomal Biogenesis Factor 5; Peroxisome Receptor 1; Peroxisomal C-Terminal Targeting Signal Import Receptor; Peroxisomal Targeting Signal 1 Receptor; Peroxisomal Import Receptor 5; PTS1 Receptor; Peroxin-5; PTS1-BP; PTS1R;
Function
Binds to the C-terminal PTS1-type tripeptide peroxisomal targeting signal (SKL-type) and plays an essential role in peroxisomal protein import.
Biological Process
Cell developmentIEA:Ensembl
Cerebral cortex cell migrationIEA:Ensembl
Cerebral cortex neuron differentiationIEA:Ensembl
Endoplasmic reticulum organizationIEA:Ensembl
Fatty acid beta-oxidationIEA:Ensembl
Mitochondrial membrane organizationIEA:Ensembl
Negative regulation of protein-containing complex assemblyManual Assertion Based On ExperimentIDA:UniProtKB
Neuromuscular processIEA:Ensembl
Neuron migrationIEA:Ensembl
Positive regulation of multicellular organism growthIEA:Ensembl
Protein import into peroxisome matrixManual Assertion Based On ExperimentIMP:UniProtKB
Protein import into peroxisome matrix, dockingManual Assertion Based On ExperimentIDA:UniProtKB
Protein import into peroxisome matrix, translocationIDA:UniProtKB
Protein import into peroxisome membraneManual Assertion Based On ExperimentIMP:UniProtKB
Protein targeting to peroxisomeIDA:UniProtKB
Protein tetramerizationIDA:UniProtKB
Very long-chain fatty acid metabolic processIEA:Ensembl
Cellular Location
Cytoplasm
Peroxisome membrane
Its distribution appears to be dynamic. It is probably a cycling receptor found mainly in the cytoplasm and as well associated to the peroxisomal membrane through a docking factor (PEX13).
Involvement in disease
Peroxisome biogenesis disorder 2A (PBD2A):
A fatal peroxisome biogenesis disorder belonging to the Zellweger disease spectrum and characterized clinically by severe neurologic dysfunction with profound psychomotor retardation, severe hypotonia and neonatal seizures, craniofacial abnormalities, liver dysfunction, and biochemically by the absence of peroxisomes. Additional features include cardiovascular and skeletal defects, renal cysts, ocular abnormalities, and hearing impairment. Most severely affected individuals with the classic form of the disease (classic Zellweger syndrome) die within the first year of life.
Peroxisome biogenesis disorder 2B (PBD2B):
A peroxisome biogenesis disorder that includes neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD), two milder manifestations of the Zellweger disease spectrum. The clinical course of patients with the NALD and IRD presentation is variable and may include developmental delay, hypotonia, liver dysfunction, sensorineural hearing loss, retinal dystrophy and vision impairment. Children with the NALD presentation may reach their teens, while patients with the IRD presentation may reach adulthood. The clinical conditions are often slowly progressive in particular with respect to loss of hearing and vision. The biochemical abnormalities include accumulation of phytanic acid, very long chain fatty acids (VLCFA), di- and trihydroxycholestanoic acid and pipecolic acid.
Rhizomelic chondrodysplasia punctata 5 (RCDP5):
A form of rhizomelic chondrodysplasia punctata, a disease characterized by severely disturbed endochondral bone formation, rhizomelic shortening of femur and humerus, vertebral disorders, dwarfism, cataract, cutaneous lesions, facial dysmorphism, and severe mental retardation with spasticity.
PTM
Monoubiquitination at Cys-11 is required for proper export from peroxisomes and recycling.
Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-PEX5 Recombinant Antibody (1D3)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare